ProShare Advisors’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.66M Sell
3,067
-620
-17% -$349K ﹤0.01% 707
2026
Q1
$2.19M Buy
3,687
+58
+2% +$28.9K ﹤0.01% 686
2025
Q4
$1.77M Buy
3,629
+94
+3% +$43.8K ﹤0.01% 709
2025
Q3
$1.48M Sell
3,535
-147
-4% -$49.4K ﹤0.01% 729
2025
Q2
$1.06M Sell
3,682
-247
-6% -$73.8K ﹤0.01% 801
2025
Q1
$1.21M Sell
3,929
-274
-7% -$93.9K ﹤0.01% 762
2024
Q4
$1.48M Sell
4,203
-4,935
-54% -$1.81M ﹤0.01% 768
2024
Q3
$3.27M Buy
9,138
+4,308
+89% +$1.46M 0.01% 600
2024
Q2
$1.54M Sell
4,830
-759
-14% -$201K ﹤0.01% 699
2024
Q1
$1.28M Buy
5,589
+117
+2% +$26.4K ﹤0.01% 740
2023
Q4
$1.2M Sell
5,472
-131
-2% -$30.2K ﹤0.01% 727
2023
Q3
$1.27M Sell
5,603
-166
-3% -$38.2K ﹤0.01% 693
2023
Q2
$1.27M Sell
5,769
-152
-3% -$33.7K ﹤0.01% 692
2023
Q1
$1.33M Sell
5,921
-1,345
-19% -$332K ﹤0.01% 693
2022
Q4
$2.02M Buy
7,266
+224
+3% +$56.5K 0.01% 625
2022
Q3
$1.48M Buy
7,042
+283
+4% +$63.3K 0.01% 667
2022
Q2
$1.59M Sell
6,759
-2,402
-26% -$488K 0.01% 684
2022
Q1
$1.64M Sell
9,161
-2,379
-21% -$453K ﹤0.01% 764
2021
Q4
$2.49M Sell
11,540
-2,229
-16% -$438K ﹤0.01% 717
2021
Q3
$2.54M Buy
13,769
+712
+5% +$140K 0.01% 664
2021
Q2
$2.34M Buy
13,057
+2,624
+25% +$500K 0.01% 687
2021
Q1
$1.75M Sell
10,433
-715
-6% -$119K 0.01% 742
2020
Q4
$1.69M Buy
11,148
+215
+2% +$28.2K 0.01% 685
2020
Q3
$1.1M Buy
10,933
+265
+2% +$29.1K 0.01% 698
2020
Q2
$1.29M Buy
10,668
+2,193
+26% +$247K 0.01% 645
2020
Q1
$804K Sell
8,475
-5,788
-41% -$550K 0.01% 637
2019
Q4
$1.26M Sell
14,263
-1,947
-12% -$171K 0.01% 730
2019
Q3
$1.29M Sell
16,210
-1,134
-7% -$91.3K 0.01% 686
2019
Q2
$1.35M Sell
17,344
-2,892
-14% -$270K 0.01% 676
2019
Q1
$2.38M Buy
20,236
+1,271
+7% +$148K 0.01% 562
2018
Q4
$2.06M Sell
18,965
-3,951
-17% -$458K 0.01% 563
2018
Q3
$2.93M Sell
22,916
-146
-0.6% -$18.1K 0.02% 531
2018
Q2
$2.61M Sell
23,062
-1,707
-7% -$188K 0.02% 570
2018
Q1
$2.78M Sell
24,769
-3,426
-12% -$435K 0.02% 552
2017
Q4
$4.17M Sell
28,195
-100
-0.4% -$12.7K 0.03% 458
2017
Q3
$3.32M Buy
28,295
+1,085
+4% +$139K 0.03% 455
2017
Q2
$3.53M Sell
27,210
-1,507
-5% -$188K 0.04% 429
2017
Q1
$3.89M Sell
28,717
-4,027
-12% -$610K 0.04% 393
2016
Q4
$4.7M Buy
32,744
+719
+2% +$91.8K 0.05% 351
2016
Q3
$3.78M Sell
32,025
-6,354
-17% -$763K 0.05% 302
2016
Q2
$4.07M Sell
38,379
-513
-1% -$57.2K 0.05% 283
2016
Q1
$4.33M Sell
38,892
-3,712
-9% -$470K 0.06% 264
2015
Q4
$6.67M Buy
42,604
+2,526
+6% +$368K 0.08% 240
2015
Q3
$5.26M Sell
40,078
-5,190
-11% -$832K 0.07% 260
2015
Q2
$7.87M Sell
45,268
-1,020
-2% -$183K 0.11% 194
2015
Q1
$7.98M Buy
46,288
+4,846
+12% +$739K 0.09% 218
2014
Q4
$5.37M Sell
41,442
-8,592
-17% -$1.11M 0.06% 308
2014
Q3
$6.44M Sell
50,034
-636
-1% -$65.6K 0.09% 227
2014
Q2
$4.48M Buy
50,670
+5,829
+13% +$561K 0.06% 332
2014
Q1
$4.22M Sell
44,841
-11,731
-21% -$1.2M 0.05% 335
2013
Q4
$6.4M Buy
56,572
+33,742
+148% +$3.04M 0.1% 216
2013
Q3
$1.8M Buy
22,830
+9,671
+73% +$707K 0.04% 466
2013
Q2
$866K Buy
+13,159
New +$848K 0.02% 942

Other funds holding UTHR

ProShare Advisors's UTHR Position: Q2 2026 in Review

ProShare Advisors reduced its United Therapeutics (UTHR) stake by 17% in Q2 2026, selling an estimated $349K and leaving 3,067 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #707.

ProShare Advisors first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.98M in Q1 2015. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • ProShare Advisors held 3,067 shares of United Therapeutics worth $1.66M as of Q2 2026.
  • ProShare Advisors sold 620 United Therapeutics shares in Q2 2026, an estimated $349K.
  • United Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #707 holding.
  • ProShare Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's United Therapeutics position peaked at $7.98M in Q1 2015.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.